Treatment of breast cancer in older women

References

• Gennari R, Curiglino G, Rotmensz N, Robertson C, Colleoni M, Zurrida S, et al. Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopausal patients. Cancer 2004; 101: 1302–10
   PubMed Web of Science ®Google Scholar
• Kimmick GG, Balducci L. Breast cancer and aging: Clinical interactions. Hematol Oncol Clin North Am 2000; 14: 213–34
   PubMed Web of Science ®Google Scholar
• Singh R, Hellman S, Heimann R. The natural history of breast carcinoma in the elderly. Cancer 2004; 100: 1807–13
   PubMed Web of Science ®Google Scholar
• Giordano SH, Hortobagyi GN, Kau SWC, Theriault RL, Bondy ML. Breast cancer treatment guidelines in older women. J Clin Oncol 2005; 23: 783–91
   PubMed Web of Science ®Google Scholar
• Aapro MS, Köhne CH, Cohen HJ, Extermann M. Never too old? Age should not be a barrier to enrolment in cancer clinical trials. The Oncologist 2005; 10: 198–204
   PubMed Web of Science ®Google Scholar
• Silliman RA. What constitutes optimal care for older women with breast cancer?. J Clin Oncol 2003; 21: 3554–6
   PubMedGoogle Scholar
• Wyld L, Reed MWR. The need for targeted research into breast cancer in the elderly. Br J Surg 2003; 90: 388–99
   PubMed Web of Science ®Google Scholar
• Newschaffer CJ, Penberthy L, Desch CE, Retchin SM, Whittemore M. The effect of age and comorbidity in the treatment of elderly women with non-metastatic breast cancer. Arch Intern Med 1996; 156: 85–90
   PubMedGoogle Scholar
• Busch E, Kemeny M, Fremgen A, Winchester DP, Clive RE. Patterns of breast cancer care in the elderly. Cancer 1996; 78: 101–11
   PubMedGoogle Scholar
• Wanebo HJ, Cole B, Chung M, Vezeridis M, Schepps B, Fulton J, et al. Is surgical management compromised in elderly patients with breast cancer?. Ann Surg 1997; 225: 579–89
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. Treatment of early-stage breast cancer. NIH consensus conference. JAMA 1991;265:391–5.
   PubMedGoogle Scholar
• Bouchardy C, Rapiti E, Fioretta G, Laissue P, Neyroud-Caspar I, Schafer P, et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 2003; 213: 580–7
   Google Scholar
• Fentiman IS, Christiaens M-R, Paridaens R, Van Geel A, Rutgers E, Berner J, et al. Treatment of operable breast cancer in the elderly: A randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy. Eur J Cancer 2003; 39: 309–16
   PubMed Web of Science ®Google Scholar
• Gazet JC, Ford HT, Coombes RC, Bland JM, Sutcliffe R, Quilliam J, et al. Prospective randomised trial of tamoxifen versus surgery in elderly patients with breast cancer. Eur J Surg Oncol 1994; 20: 207–14
   PubMedGoogle Scholar
• Kenny FS, Robertson JFR, Ellis IO, Elston CW, Blarney RW. Long-term follow-up of elderly patients randomised to primary tamoxifen or wedge mastectomy as initial therapy for operable breast cancer. The Breast 1998; 7: 335–9
   Web of Science ®Google Scholar
• Fennessy M, Bates T, Macrae K, Riley D, Houghton J, Baum M. Late follow-up of a randomised trial of surgery plus tamoxifen versus tamoxifen alone in women over 70 years with operable breast cancer. Br J Surg 2004; 91: 699–704
   PubMed Web of Science ®Google Scholar
• Mustacchi G, Ceccherini R, Milani S, Pluchinotta A, De Matteis A, Maiorino L, et al. Tamoxifen alone versus adjuvant tamoxifen as for operable breast cancer of the elderly: Long-term results of the phase III randomized multicenter GRETA Trial. Ann Oncol 2003; 14: 414–20
   PubMed Web of Science ®Google Scholar
• Hind D, Wyld L, Beverley CB, Reed MW. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). The Cochrane Database of Systematic Reviews 2006 Issue 1. Art No.: CD004272.
   Google Scholar
• Gori J, Castaño R, Engel H, Toziano M, Fischer C, Maletti G. Conservative treatment vs. mastectomy without radiotherapy in aged women with breast cancer – a prospective and randomized trial. Zentralbl Gynäkol 2000; 122: 311–7
   PubMedGoogle Scholar
• Fentiman IS, van Zijl J, Karydas I, Chaudary MA, Margreiter R, Legrand C, et al. Treatment of operable breast cancer in the elderly: A randomised clinical trial EORTC 10850 comparing modified radical mastectomy with tumourectomy plus tamoxifen. Eur J Cancer 2003; 39: 300–8
   PubMed Web of Science ®Google Scholar
• Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival – a Bayesian meta-analysis. Ann Surg Oncol 1999; 6: 109–16
   PubMed Web of Science ®Google Scholar
• DiFronzo LA, Hansen NM, Stern SL, Brennan MB, Giuliano AE. Does sentinel lymphadenectomy improve staging and alter therapy in elderly women with breast cancer?. Ann Surg Oncol 2000; 7: 406–10
   PubMedGoogle Scholar
• McMahon LE, Gray RJ, Pockaj BA. Is breast cancer sentinel node mapping valuable for patients in their seventies and beyond?. Am J Surg 2005; 190: 366–70
   PubMed Web of Science ®Google Scholar
• Martelli G, Boracchi P, De Palo M, Pilotti S, Oriana S, Zucali R, et al. A randomized trial comparing axillary dissection to no axillary surgery in older patients with T1N0 breast cancer. Ann Surg 2005; 242: 1–6
   PubMed Web of Science ®Google Scholar
• International Breast Cancer Study Group. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: First results of International Breast Cancer Study Group Trial 10–93. J Clin Oncol 2006;24:337–44.
   PubMedGoogle Scholar
• August DA, Wilkins E, Rea T. Breast reconstruction in older women. Surgery 1994; 115: 663–8
   PubMedGoogle Scholar
• Girotto JA, Schreiber J, Nahabedian MY. Breast reconstruction in the elderly: Preserving excellent quality of life. Ann Plast Surg 2003; 50: 572–8
   PubMedGoogle Scholar
• Handel N, Silverstein MJ, Waisman E, Waisman JR. Reasons why mastectomy patients do not have breast reconstruction. Plast Reconstr Surg 1990; 86: 1118–22
   PubMedGoogle Scholar
• Reaby LL. Reasons why women who have had mastectomy decide to have or not to have breast reconstruction. Plast Reconstr Surg 1998; 101: 1810–8
   PubMed Web of Science ®Google Scholar
• Serietti JM, Higgins JP, Moran S, Orlando GS. Factors affecting outcome in free-tissue transfer in the elderly. Plast Reconstr Surg 2000; 106: 66–70
   PubMedGoogle Scholar
• Lipa JE, Youssef AA, Kuerer HM, Robb GL, Chang DW. Breast reconstruction in older women: Advantages of autogenous tissue. Plast Reconstr Surg 2003; 111: 1110–21
   PubMed Web of Science ®Google Scholar
• Bowman CC, Lennox PA, Clugston PA, Courtemache DJ. Breast reconstruction in older women: Should age be an exclusion criterion?. Plast Reconstr Surg 2006; 118: 16–22
   PubMed Web of Science ®Google Scholar
• Liang W, Burnett CB, Rowland JH, Meropol NJ, Eggert L, Hwang YT, et al. Communication between physicians and older women with breast cancer: Implications for treatment and patient satisfaction. J Clin Oncol 2002; 20: 1008–16
   PubMedGoogle Scholar
• De Haes JCJM, Curran D, Aaronson NK, Fentiman IS. Quality of life in breast cancer patients aged over 70 years, participating in the EORTC 10850 randomised clinical trial. Eur J Cancer 2003; 39: 945–51
   PubMed Web of Science ®Google Scholar
• Mandelblatt JS, Edge SB, Meropol NJ, Senie R, Tsangaris T, Grey L, et al. Predictors of long-term outcomes in older breast cancer survivors: Perceptions versus patterns of care. J Clin Oncol 2003; 21: 855–63
   PubMed Web of Science ®Google Scholar
• Figueiredo MI, Cullen J, Hwang YT, Rowland JH, Mandelblatt JS. Breast cancer treatment in older women: Does getting what you want improve your long-term body image and mental health?. J Clin Oncol 2004; 22: 4002–9
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists Collaborative Group. Favorable and unfavorable effects on long term survival of radiotherapy for early stage breast cancer: An overview of randomized trials. Lancet 2000;355:1757–70.
   PubMedGoogle Scholar
• Fisher B, Anderson S. Conservative surgery for the management of invasive and non-invasive carcinoma of the breast: NSABP trials. World J Surg 1994; 18: 63–9
   PubMed Web of Science ®Google Scholar
• Hillner BE, Mandelblatt J. Caring for older women with breast cancer: Can observational research fill the clinical trial gap?. J Natl Cancer Inst 2006; 98: 660–1
   PubMedGoogle Scholar
• Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 2004; 351: 971–7
   PubMed Web of Science ®Google Scholar
• Carlson RW, Anderson BO, Burstein HJ. Breast Cancer. J Natl Compr Canc Netw 2005; 3: 238–89
   PubMedGoogle Scholar
• Smith BD, Gross CP, Smith GL, Galusha DH, Bekelman JE, Haffty BG. Effectiveness of radiation therapy for older women with early breast cancer. J Natl Cancer Inst 2006; 98: 681–90
   PubMedGoogle Scholar
• Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcomes of elderly women with breast cancer. J Natl Cancer Inst 2000; 92: 550–6
   PubMed Web of Science ®Google Scholar
• Benhaim DI, Lopchinsky R, Tartter PI. Lumpectomy with tamoxifen as primary treatment for elderly women with early-stage breast cancer. Am J Surg 2000; 180: 162–6
   PubMedGoogle Scholar
• McCready DR, Chapman JA, Hanna WM, Kahn HJ, Yap K, Fish EB, et al. Factors associated with local breast cancer recurrence after lumpectomy alone: Post-menopausal patients. Ann Surg Oncol 2000; 7: 562–7
   PubMed Web of Science ®Google Scholar
• De Csepel J, Tartter PI, Gajdos C. When not to give radiation therapy after breast conservation surgery for breast cancer. J Surg Oncol 2000; 74: 273–7
   PubMedGoogle Scholar
• Truong PT, Bernstein V, Lesperance M, Speers CH, Olivotto IA. Radiotherapy omission after breast-conserving surgery is associated with reduced breast cancer-specific survival in elderly women with breast cancer. Am J Surg 2006; 191: 749–55
   PubMed Web of Science ®Google Scholar
• Livi L, Paiar F, Meldolesi E, Bianchi S, Cardona G, Cataliotti L, et al. The management of elderly patients with T1–T2 breast cancer treated with or without radiotherapy. Eur J Surg Oncol 2005; 31: 473–8
   PubMedGoogle Scholar
• Whelan TJ, Julian J, Wright J, Jadad AR, Levine ML. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol 2000; 18: 1220–9
   PubMed Web of Science ®Google Scholar
• Recht A, Edge SB, Solin LJ, Robinson DS, Estabrook A, Fine RE, et al. Post-mastectomy radiotherapy: Guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1539–69
   PubMed Web of Science ®Google Scholar
• Lee JC, Truong PT, Kader HA, Speers CH, Olivotto IA. Postmastectomy radiotherapy reduces locoregional recurrence in elderly women with high-risk breast cancer. Clin Oncol 2005; 17: 623–9
   Web of Science ®Google Scholar
• Punglia RS, Weeks JC, Neville BA, Earle CC. Radiation therapy after mastectomy between 1991 and 1999 in elderly women: Response to clinical trial information. J Clin Oncol 2006; 24: 3474–82
   PubMedGoogle Scholar
• Holmes CE, Muss HB. Diagnosis and treatment of breast cancer in the elderly. CA Cancer J Clin 2003; 53: 227–44
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687–717.
   PubMed Web of Science ®Google Scholar
• Ragaz J, Coldman A. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. J Clin Oncol 1998; 16: 2018–24
   PubMed Web of Science ®Google Scholar
• Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081–92
   PubMed Web of Science ®Google Scholar
• Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005; 365: 60–2
   PubMed Web of Science ®Google Scholar
• Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366: 455–62
   PubMed Web of Science ®Google Scholar
• Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353(26)2747–57
   PubMed Web of Science ®Google Scholar
• Boccardo F, Rubagotti A, Guglielmini P, Fini A, Paladini G, Mesiti M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 2006; 17(Suppl 7)vii10–vii14
   PubMedGoogle Scholar
• Mouridsen HT. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women. Curr Med Res Opin 2006; 22: 1609–21
   PubMed Web of Science ®Google Scholar
• Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, et al. American Society of Clinical Oncology 2003 Update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21: 4042–57
   PubMed Web of Science ®Google Scholar
• Brufsky A. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: A Z-FAST update. Semin Oncol 2006; 33(2 Suppl 7)S13–7
   PubMedGoogle Scholar
• Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, et al. Assessment of quality of life in MA.17: A randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005; 23: 6931–40
   PubMed Web of Science ®Google Scholar
• Fallowfield LJ, Bliss JM, Porter LS, Price MH, Snowdon CF, Jones SE, et al. Quality of life in the intergroup exemestane study: A randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 2006; 24: 910–7
   PubMed Web of Science ®Google Scholar
• Mano M, Fraser G, McIlroy P, Stirling L, MacKay H, Ritchie D, et al. Locally advanced breast cancer in octogenarian women. Breast Cancer Res Treat 2005; 89: 81–90
   PubMedGoogle Scholar
• Freedman OC, Verma S, Clemons MJ. Using aromatase inhibitors in the neoadjuvant setting: Evolution or revolution?. Cancer Treat Rev 2005; 31: 1–17
   PubMedGoogle Scholar
• Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005; 23: 5108–16
   PubMed Web of Science ®Google Scholar
• Cataliotti L, Buzdar AU, Noguchi S, Bines J, Takatsuka Y, Petrakova K, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: The Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial. Cancer 2006; 106: 2095–103
   PubMed Web of Science ®Google Scholar
• Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 2001; 12: 1527–32
   PubMed Web of Science ®Google Scholar
• Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, et al. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 2006; 24: 3019–25
   PubMed Web of Science ®Google Scholar
• Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 2000; 341: 2061–7
   Google Scholar
• Hébert-Croteau N, Brisson J, Latreille J, Rivard M, Abdelaziz N, Martin G. Compliance with consensus recommendations for the treatment of early stage breast carcinoma in elderly women. Cancer 1999; 85: 1104–13
   PubMed Web of Science ®Google Scholar
• Du XL, Goodwin JS. Patterns of use of chemotherapy for breast cancer in older women: Findings from Medicare claims data. J Clin Oncol 2001; 19: 1455–61
   PubMed Web of Science ®Google Scholar
• Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 2005; 23: 3112–24
   PubMed Web of Science ®Google Scholar
• Pierga JY, Girre V, Laurence V, Asselain B, Dieras V, Jouve M, et al. Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age. The Breast 2004; 13: 369–75
   PubMed Web of Science ®Google Scholar
• Elkin EB, Hurria A, Mitra N, Schrag D, Panageas KS. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: Assessing outcome in a population-based, observational cohort. J Clin Oncol 2006; 24: 2757–64
   PubMed Web of Science ®Google Scholar
• Giordano SH, Duan Z, Kuo F-Y, Hortobagyi GN, Goodwin JS. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 2006; 24: 2750–6
   PubMed Web of Science ®Google Scholar
• Muss HB, Woolf S, Berry D, Cirrincione C, Weiss RB, Budman D, Wood WC, Henderson IC, Hudis C, Winer E, Cohen H, Wheeler J, Norton L, Cancer and Leukemia Group B. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005; 293: 1073–81
   PubMed Web of Science ®Google Scholar
• Pritchard KI, Paterson AH, Fine S, Paul NA, Zee B, Shepher LE, et al. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: A report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group. J Clin Oncol 1997; 15: 2302–11
   PubMed Web of Science ®Google Scholar
• Crivellari D, Bonetti M, Castiglione-Gertsch M, Gelber RD, Rudenstam CM, Thurlimann B, et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, fluorouracil and taxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII. J Clin Oncol 2000; 18: 1412–22
   PubMed Web of Science ®Google Scholar
• De Maio E, Gravina A, Pacilio C, Amabile G, Labonia V, Landi G, et al. Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: A single-center experience. BMC Cancer 2005; 5: 30
   PubMedGoogle Scholar
• Fisher B, Redmond C, Legault-Poisson S, Dimitrov NV, Brown AM, Wickerham DL, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 1990; 8: 1005–18
   PubMed Web of Science ®Google Scholar
• Wils JA, Bliss JM, Marty M, Coombes G, Fontaine C, Morvan F, et al. Epirubicin plus tamoxifen vs tamoxifen alone in node-positive postmenopausal patients with breast cancer: A randomized trial of the International Collaborative Cancer Group. J Clin Oncol 1999; 17: 1988–98
   PubMed Web of Science ®Google Scholar
• Fargeot P, Bonneterre J, Rochè H, Lortholary A, Campone M, Van Praagh I, et al. Disease-free survival advantage of weekly Epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French Adjuvant Study Group 08 trial. J Clin Oncol 2004; 23: 4622–30
   Google Scholar
• Giordano SH, Pinder M, Duan Z, Hortobagyi G, Goodwin J. Congestive heart failure in older women treated with anthracycline (A) chemotherapy (C). Proc ASCO 2006; 521 (abstract).
   Google Scholar
• Leonard RCF, Malinovszky KM. Chemotherapy for older women with early breast cancer. Clin Oncol 2005; 17: 244–8
   Google Scholar
• Mouridsen H, Chaudri-Ross HA. Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer. Oncologist 2004; 9: 497–506
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Bonneterre J, Buzdar A, Robertson JF, Thurlimann B. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Survival analysis and updated safety results. Eur J Cancer 2003; 39: 1684–9
   PubMed Web of Science ®Google Scholar
• Bonneterre J, Buzdar A, Nabholtz A, Robertson JF, Thurlimann B, von Euler M, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Results of two randomized trials designed for combined analysis. Cancer 2001; 92: 2247–58
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003; 21: 2101–9
   PubMed Web of Science ®Google Scholar
• Paridaens R, Therasse P, Dirix L, Beex L, Piccart M, Cameron D, et al. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) – A randomized phase III trial of the EORTC Breast Group. J Clin Oncol [ASCO Annual Meeting Proceedings (Post-Meeting Edition)] 2004;22: (14S):515 (abstract).
   Google Scholar
• Ferretti G, Bria E, Giannarelli D, Felici A, Papaldo P, Fabi A, et al. Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: A pooled analysis of the randomized trials. Br J Cancer 2006; 94: 1789–96
   PubMed Web of Science ®Google Scholar
• Lewis-Wambi JS, Jordan VC. Treatment of postmenopausal breast cancer with selective estrogen receptor modulators (SERMs). Breast Dis 2005–2006; 24: 93–105
   PubMedGoogle Scholar
• Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials. Cancer 2003; 98: 229–38
   PubMed Web of Science ®Google Scholar
• Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 2004; 22: 1605–13
   PubMed Web of Science ®Google Scholar
• Cheung KL, Owers R, Robertson JF. Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: Experience from a single centre. Endocr Relat Cancer 2006; 13: 251–5
   PubMed Web of Science ®Google Scholar
• Marcom PK, Isaacs C, Harris L, Wong ZW, Kommarreddy A, Noviellie N, et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 2006; [Epub ahead of print].
   PubMedGoogle Scholar
• Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 2003; 97: 2869–79
   PubMed Web of Science ®Google Scholar
• Li J, Gwilt PR. The effect of age on the early disposition of doxorubicin. Cancer Chemother Pharmacol 2003; 51: 395–402
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Burris HA 3rd, Billings FT 3rd, Bradof JE, Baker M, Greco FA. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer. J Clin Oncol 2001; 19: 3500–5
   PubMed Web of Science ®Google Scholar
• Del Mastro L, Perrone F, Repetto L, Manzione L, Zagonel V, Fratino L, et al. Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: A phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). Ann Oncol 2005; 16: 253–8
   PubMed Web of Science ®Google Scholar
• Feher O, Vodvarka P, Jassem J, et al. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: A multicenter, randomised, phase III study. Ann Oncol 2005; 16: 899–908
   PubMed Web of Science ®Google Scholar
• Repetto L, Vannozzi MO, Balleari E, et al. Mitoxantrone in elderly patients with advanced breast cancer: Pharmacokinetics, marrow and peripheral hematopoietic progenitor cells. Anticancer Res 1999; 19: 879–84
   PubMed Web of Science ®Google Scholar
• Vogel C, O'Rourke M, Winer E, et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol 1999; 10: 397–402
   PubMed Web of Science ®Google Scholar
• Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005; 23: 1–7
   PubMedGoogle Scholar
• Crivellari D, Lombardi D, Corona G, et al. Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: Comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring. Ann Oncol 2006; 17: 807–12
   PubMed Web of Science ®Google Scholar
• O'Brien M.E.R., Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCI (Caelyx/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15: 440–9
   PubMed Web of Science ®Google Scholar
• Harris L, Batist G, Belt R, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002; 94: 25–36
   PubMed Web of Science ®Google Scholar
• Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The MD Anderson Cancer Center Experience. J Clin Oncol 2006; 24: 4107–15
   PubMed Web of Science ®Google Scholar
• Miller KD, Wang M, Gralow J, et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 2005; 94(Suppl 1)S6
   Google Scholar
• Nicholson RI, McClelland RA, Robertson JF, et al. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 1999; 6: 373–87
   PubMed Web of Science ®Google Scholar
• Schnell FM. Chemotherapy-induced nausea and vomiting: The importance of acute antiemetic control. The Oncologist 2003; 8: 187–98
   PubMed Web of Science ®Google Scholar
• Ozer H, Armitage JO, Bennett CL, et al. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000; 18: 3558–85
   PubMed Web of Science ®Google Scholar
• Repetto L, Carreca I, Maraninchi D, et al. Use of growth factors in the elderly patients with cancer: A report from the Second International Society for Geriatric Oncology (SIOG) 2001 meeting. Crit Rev Oncol Hematol 2003; 45: 123–8
   PubMedGoogle Scholar